Wedbush Reaffirms Outperform Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They currently have a $9.00 target price on the stock, down from their previous target price of $11.00. Wedbush’s price target would indicate a potential upside of 114.29% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Citigroup initiated coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, January 27th. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target for the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Stock Performance

Shares of VYGR traded down $1.12 during mid-day trading on Tuesday, hitting $4.20. The company’s stock had a trading volume of 1,381,874 shares, compared to its average volume of 368,334. The stock’s 50-day moving average is $5.74 and its two-hundred day moving average is $6.37. The firm has a market capitalization of $229.45 million, a PE ratio of 5.92 and a beta of 0.91. Voyager Therapeutics has a one year low of $4.13 and a one year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period last year, the business posted ($0.59) EPS. Analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its position in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock valued at $747,000 after acquiring an additional 5,365 shares during the period. Hunter Perkins Capital Management LLC increased its stake in Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Voyager Therapeutics by 7.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock worth $801,000 after purchasing an additional 9,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the period. Finally, Empowered Funds LLC increased its position in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.